A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small cell lung cancer.
Noura J ChoudhuryW Victoria LaiAlex MakhninGlenn HellerJuliana EngBob T LiIsabel R PreeshagulFernando C SantiniMichael D OffinKenneth NgPaul K PaikChristina LarsenMichelle S GinsbergYvonne LauXinyuan ZhangMarina K BaineNatasha RekhtmanCharles M RudinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Valemetostat and irinotecan was not tolerated but demonstrated efficacy in recurrent SCLC. Valemetostat may warrant further investigation in SCLC.
Keyphrases